Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer.
about
Chemotherapy-related cognitive impairment in older patients with cancerWeight change during chemotherapy changes the prognosis in non metastatic breast cancer for the worse.Prevalence, mechanisms, and management of cancer-related cognitive impairment.Optical imaging of breast cancer oxyhemoglobin flare correlates with neoadjuvant chemotherapy response one day after starting treatment.Tissue polypeptide antigen & interleukin-6: Are their serum levels a predictor for response to chemotherapy in breast cancer?Leptin pro-angiogenic signature in breast cancer is linked to IL-1 signalling.An update on cancer- and chemotherapy-related cognitive dysfunction: current status.Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism?Tai chi, cellular inflammation, and transcriptome dynamics in breast cancer survivors with insomnia: a randomized controlled trial.Differential expression of cytokines in breast cancer patients receiving different chemotherapies: implications for cognitive impairment research.Fatigue and sleep quality are associated with changes in inflammatory markers in breast cancer patients undergoing chemotherapy.Baseline immune biomarkers as predictors of MBSR(BC) treatment success in off-treatment breast cancer patientsSleep disturbance, inflammation and depression risk in cancer survivorsRapid Extensive Recurrence of Triple Negative Breast Cancer: Are Both Therapy and Cancer Biology the Culprit?Prevalence, putative mechanisms, and current management of sleep problems during chemotherapy for cancerIntraoperative imaging identifies thymoma margins following neoadjuvant chemotherapy.Inflammation at the intersection of behavior and somatic symptoms.Depression and insomnia in cancer: prevalence, risk factors, and effects on cancer outcomes.Circadian disruption, fatigue, and anorexia clustering in advanced cancer patients: implications for innovative therapeutic approaches.The role of intratumoral and systemic IL-6 in breast cancer.The biology of depression in cancer and the relationship between depression and cancer progression.Predictive value of HDL cholesterol for cancer-associated venous thromboembolism during chemotherapy.Serum N-glycome alterations in breast cancer during multimodal treatment and follow-up.Prevalence, predictors, and prognostic impact of fatigue among Brazilian outpatients with advanced cancers.Immunological effects of taxol and adryamicin in breast cancer patients.Carvedilol Attenuates Inflammatory-Mediated Cardiotoxicity in Daunorubicin-Induced Rats.Assessment of chemotherapy on various biochemical markers in breast cancer patients.Associations between inflammatory markers and cognitive function in breast cancer patients receiving chemotherapy.The circadian rest-activity rhythm, a potential safety pharmacology endpoint of cancer chemotherapy.Network and Pathway Analysis of Toxicogenomics Data
P2860
Q26747612-A5FBC033-3A01-425F-BE44-2B47D66111B5Q30992559-8D8AE7FC-CD94-406B-86EA-BD0BEC614D4BQ33854977-06920E02-78E7-46C3-A8E2-0BB91920D76BQ33996547-029781D9-EE57-4E99-B6C9-A18DC20EEFA5Q34176287-2184440A-9090-481B-9E25-0C7DE0D9A462Q34577547-CD5AB144-F4E9-44EE-B417-0132A3A5D99DQ35059702-EC0E73FD-CCCF-4B1C-8578-E96ABD3BC48CQ35229735-A17E92BA-B107-425F-92C5-6434BA74978BQ35543976-7A5F65CA-4E73-4AE0-BE14-00069E1D907BQ35556085-56D77C6F-947C-4F87-83D0-8D836407D6ECQ36024587-44563E3D-79CA-4FC8-9CE5-1B67AC631ADFQ36159062-B42A6D68-39BF-428B-8B86-9641AB9874D8Q36213531-ED24541D-49A4-4E61-A6C8-D551457BE3C9Q36429758-889896C7-94B0-4AF0-97B8-F4A6D113CC10Q36671163-EE4B8AB9-2CCA-4613-B56C-E1E2D9229257Q36772031-34D19BAA-521A-4B2E-BB96-FFEC3FA8FB31Q37287493-0F1C6834-7BD6-4362-A085-92731705A928Q37331962-D991DD70-3DE5-4903-856C-27432617D4ABQ37668544-64F920BA-9B66-4E5C-A0AF-B970BD8FBF9AQ38093468-ED91892A-D3F2-450C-A473-AA6DB242BC66Q38203302-B17CE562-2FC6-41CE-A0F1-C171C126EAD6Q39123264-4CF7695C-1907-4E94-9AC1-91573F4B35D7Q42005818-D7A59873-25AB-43BB-962F-72D2E6C15338Q44833987-1DE81388-2748-43C5-B7D8-9102CF799A2BQ45661616-DF669859-A033-40FA-913A-4B81C8E734DFQ46930825-F00E97BF-93F1-4EC6-BC99-1550BCACF1D9Q48335444-94AE534F-0EBF-4CD7-B4A7-9A9F9420C929Q50059476-F5DB38CB-CA97-47A1-A7D6-13689CF33899Q52647652-D15FDB52-DB29-4D2E-83DA-2AD8B143EE39Q58580378-A2333337-8925-4FA7-8FA6-1CB338F0A449
P2860
Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Predictors of inflammation in ...... hemotherapy for breast cancer.
@ast
Predictors of inflammation in ...... hemotherapy for breast cancer.
@en
type
label
Predictors of inflammation in ...... hemotherapy for breast cancer.
@ast
Predictors of inflammation in ...... hemotherapy for breast cancer.
@en
prefLabel
Predictors of inflammation in ...... hemotherapy for breast cancer.
@ast
Predictors of inflammation in ...... hemotherapy for breast cancer.
@en
P2093
P2860
P1476
Predictors of inflammation in ...... hemotherapy for breast cancer.
@en
P2093
Barbara Parker
Georgia R Sadler
Loki Natarajan
Paul J Mills
Roland von Känel
Shamini Jain
P2860
P304
P356
10.1016/J.BBI.2007.07.001
P577
2007-08-15T00:00:00Z